Meet Merck’s Dealmaker: A Conversation With Roger Pomerantz
Merck’s new head of worldwide licensing and knowledge management Roger Pomerantz, MD, talks with IN VIVO about Merck’s business development strategy, whether biotech passion can exist on a Big Pharma scale, and the art of the deal.
You may also be interested in...
At Elsevier Business Intelligence's recent Therapeutic Area Partnerships conference, a roundtable of senior pharmaceutical executives and entrepreneurs weighed in on industry’s current funding challenges, how dealmaking defines a biotech’s ambitions and strategy, and pharma’s appetite for early-stage innovation.
Big pharma collaborations and other new or once-rare models of business development can help companies ‘do more with less’, according to AstraZeneca’s and Merck’s heads of business development, who spoke at Elsevier’s Pharmaceutical Strategic Alliances conference.
Newly named chairman, Merck’s CEO Ken Frazier, cites several – smallish – launches, flexibility, especially in the face of setbacks, and business development, and ongoing focus on innovation as priorities in 2012 that will lead to long-term sustainability.